KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) to Post FY2023 Earnings of ($3.56) Per Share, Cantor Fitzgerald Forecasts

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) – Equities research analysts at Cantor Fitzgerald lifted their FY2023 earnings per share estimates for KalVista Pharmaceuticals in a research note issued to investors on Tuesday, April 11th. Cantor Fitzgerald analyst C. Duncan now forecasts that the specialty pharmaceutical company will post earnings of ($3.56) per share for […]

Related Keywords

Benjaminl Palleiko ,Thomas Andrew Crockett ,Opaleye Management Inc ,Cantor Fitzgerald ,Nasdaq ,Institutional Investors Weigh In On Kalvista Pharmaceuticals ,Vr Adviser ,Kalvista Pharmaceuticals ,Kalvista Pharmaceuticals Inc ,News Ratings For Kalvista Pharmaceuticals Daily ,Securities Exchange Commission ,Tang Capital Management ,Needham Company ,Jefferies Financial Group Inc ,Frazier Life Sciences Management ,Kalvista Pharmaceuticals Price Performance ,Get Rating ,Kalvista Pharmaceutical ,Vista Pharmaceuticals ,Exchange Commission ,Andrew Crockett ,Capital Management ,Financial Group ,Opaleye Management ,Kalvista Pharmaceuticals Daily ,Nasdaq Kalv ,Kalv ,Medical ,Earnings Estimates ,